Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | ESR1 | P03372 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 3/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3219456 | 0.86 | IDO1 (0.50) | ALDH1A1HPGDMAPTNPC1RAB9A | |
| SCHEMBL1184050 | 0.85 | ALDH1A1 (0.55) | ALDH1A1HPGDMAPTNPC1RAB9A | |
| SCHEMBL10852754 | 0.82 | CA1 (0.60) | ALDH1A1HPGDMAPTNPC1RAB9A | |
| SCHEMBL14899092 | 0.81 | POLB (0.67) | ALDH1A1HPGDESR1MAPTNPC1 | |
| SCHEMBL2306741 | 0.80 | KMT2A (0.69) | ALDH1A1HPGDNPC1RAB9AKMT2A | |
| SCHEMBL7211300 | 0.80 | NPC1 (0.66) | ALDH1A1HPGDESR1MAPTNPC1 | |
| SCHEMBL2648754 | 0.79 | CA1 (0.57) | ALDH1A1HPGDMAPTNPC1RAB9A | |
| SCHEMBL2650449 | 0.79 | HDAC1 (0.58) | ALDH1A1MAPTNPC1RAB9APOLB | |
| SCHEMBL29651075 | 0.79 | CA1 (0.58) | ALDH1A1HPGDMAPTNPC1RAB9A | |
| SCHEMBL4847668 | 0.79 | CA1 (0.58) | ALDH1A1HPGDMAPTNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108147972-B | Preparation method of vipatavir intermediate and analogue thereof | 成都西岭源药业有限公司 | 2020-07-10 | — | — | CN | disclosed |
| US-10632125-B2 | MTH1 inhibitors for treatment of inflammatory and autoimmune conditions | THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING (SE) | 2020-04-28 | — | — | US | disclosed |
| US-10179790-B2 | MTH1 inhibitors for treatment of cancer | THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING (SE) | 2019-01-15 | — | — | US | disclosed |
| US-20190000856-A1 | MTH1 INHIBITORS FOR TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS | THOMAS HELLEDAYS STIFTELSE FOER MEDICINSK FORSKNING (SE) | 2019-01-03 | — | — | US | disclosed |
| US-10064869-B2 | MTH1 inhibitors for treatment of inflammatory and autoimmune conditions | THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING (SE) | 2018-09-04 | — | — | US | disclosed |
| US-20170196873-A1 | MTH1 INHIBITORS FOR TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS | THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING (SE) | 2017-07-13 | — | — | US | disclosed |
| US-20170197976-A1 | MTH1 INHIBITORS FOR TREATMENT OF CANCER | THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING (SE) | 2017-07-13 | — | — | US | disclosed |
| EP-3151833-A1 | MTH1 INHIBITORS FOR TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS | Thomas Helledays Stiftelse För Medicinsk Forskning (SE) | 2017-04-12 | — | — | EP | disclosed |
| EP-3152195-A1 | MTH1 INHIBITORS FOR TREATMENT OF CANCER | Thomas Helledays Stiftelse För Medicinsk Forskning (SE) | 2017-04-12 | — | — | EP | disclosed |
| WO-2015187088-A1 | MTH1 INHIBITORS FOR TREATMENT OF CANCER | THOMAS HELLEDAYS STIFTELSE FÖR MEDICINSK FORSKNING (SE) | 2015-12-10 | — | — | WO | disclosed |
| EP-1372660-A2 | A COMBINATION OF FBPASE INHIBITORS AND ANTIDIABETIC AGENTS USEFUL FOR THE TREATMENT OF DIABETES | Metabasis Therapeutics, Inc. (US) | 2004-01-02 | — | — | EP | disclosed |
| US-20030073728-A1 | Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes | METABASIS THERAPEUTICS, INC. | 2003-04-17 | — | — | US | disclosed |
| EP-1265907-A2 | NOVEL ARYL FRUCTOSE-1,6-BISPHOSPHATASE INHIBITORS | Metabasis Therapeutics, Inc. (US) | 2002-12-18 | — | — | EP | disclosed |
| US-20020040014-A1 | Novel aryl fructose-1,6-Bisphosphatase inhibitors | METABASIS THERAPEUTICS, INC. | 2002-04-04 | — | — | US | disclosed |
| WO-2002003978-A2 | A COMBINATION OF FBPase INHIBITORS AND ANTIDIABETIC AGENTS USEFUL FOR THE TREATMENT OF DIABETES | METABASIS THERAPEUTICS, INC. (US) | 2002-01-17 | — | — | WO | disclosed |
| WO-2001066553-A2 | NOVEL ARYL FRUCTOSE-1,6-BISPHOSPHATASE INHIBITORS | METABASIS THERAPEUTICS, INC. (US) | 2001-09-13 | — | — | WO | disclosed |
| WO-1993012795-A1 | QUINAZOLIN-4(3H)-ONE DERIVATIVES AS ANTICOCCIDIAL AGENTS | GLAZER EDWARD A (US) | 1993-07-08 | — | — | WO | disclosed |
| US-4920224-A | CHEMICAL INTERMEDIATES | PFIZER INC. (US) | 1990-04-24 | — | — | US | disclosed |
| US-4849518-A | ANTIPROTOZOA IN POULTRY | PFIZER INC. (US) | 1989-07-18 | — | — | US | disclosed |
| US-4762838-A | Quinazolin-4(3H)-one derivatives as anticoccidial agents | PFIZER INC. (US) | 1988-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073728-A1 | Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes | FBP1, ALDOA, G6PC1 | ALDH1A1 2627/4885HPGD 1298/4885ESR1 4619/4885 |
| US-10179790-B2 | MTH1 inhibitors for treatment of cancer | MTHFD1, MTHFD2, DPYD | ALDH1A1 103/4885HPGD 275/4885ESR1 4582/4885 |
| US-20020040014-A1 | Novel aryl fructose-1,6-Bisphosphatase inhibitors | FBP1, SLC5A1, G6PC1 | ALDH1A1 228/4885HPGD 1438/4885ESR1 4031/4885 |
| US-20190000856-A1 | MTH1 INHIBITORS FOR TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS | MTHFD1, MTHFD2, TPMT | ALDH1A1 240/4885HPGD 452/4885ESR1 4825/4885 |
| US-20170197976-A1 | MTH1 INHIBITORS FOR TREATMENT OF CANCER | MTHFD1, MTHFD2, DPYD | ALDH1A1 103/4885HPGD 275/4885ESR1 4582/4885 |
| US-10632125-B2 | MTH1 inhibitors for treatment of inflammatory and autoimmune conditions | MTHFD1, MTHFD2, TPMT | ALDH1A1 240/4885HPGD 452/4885ESR1 4825/4885 |
| US-20170196873-A1 | MTH1 INHIBITORS FOR TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS | MTHFD1, MTHFD2, TPMT | ALDH1A1 240/4885HPGD 452/4885ESR1 4825/4885 |
| US-10064869-B2 | MTH1 inhibitors for treatment of inflammatory and autoimmune conditions | MTHFD1, MTHFD2, TPMT | ALDH1A1 240/4885HPGD 452/4885ESR1 4825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.